Recombinant botulinum vaccine A/B clinical trials
How each study uses recombinant botulinum vaccine A/B is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- rBV A/B
- 5
Studies by the year they started
5 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
California Department of Public Health (3) · DynPort Vaccine Company LLC, A GDIT Company (2)
Studies
Open first, then newest update. How each study uses recombinant botulinum vaccine A/B is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®CompletedPhase 2California Department of Public HealthNCT06112834Written as rBV A/B
- Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®CompletedPhase 2California Department of Public HealthNCT03676634Written as rBV A/B
- Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/BWithdrawnPhase 3DynPort Vaccine Company LLC, A GDIT CompanyNCT01940315Written as rBV A/B
- Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum ToxoidCompletedPhase 2California Department of Public HealthNCT01701999Written as rBV A/B
- Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy AdultsCompletedPhase 1DynPort Vaccine Company LLC, A GDIT CompanyNCT00098098Written as rBV A/B